



YOUR GUIDE FROM EARLY DIAGNOSIS TO TREATMENT

An overview of the LEQEMBI®
treatment pathway for early
Alzheimer's disease (AD)

Lance is an actual LEQEMBI patient.
People shown were compensated for their time,
and information is accurate as of April 2025.

INDICATION

LEQEMBI® is indicated for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

SELECT SAFETY INFORMATION

WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA)

- Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause ARIA, characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events, including seizure and status epilepticus, can occur. ARIA can be fatal. Serious intracerebral hemorrhages (ICH) >1 cm, some of which have been fatal, have been observed with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI.
- **Apolipoprotein E ε4 (ApoE ε4) Homozygotes:** Patients who are ApoE ε4 homozygotes (~15% of patients with AD) treated with this class of medications have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed, they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA.
- Consider the benefit of LEQEMBI for the treatment of AD and the potential risk of serious ARIA events when deciding to initiate treatment with LEQEMBI.

Please see additional Select Safety Information throughout.

Please see full [Prescribing Information](#) for LEQEMBI, including Boxed WARNING.

Steps from diagnosis to treatment with LEQEMBI®

Step 1

Assess patient eligibility and readiness for LEQEMBI

Step 2

Evaluate ARIA risk and prepare to start treatment

Step 3

Initiate treatment and monitor

Lance is an actual LEQEMBI patient and Liz is his care partner. People shown were compensated for their time, and information is accurate as of April 2025.

ARIA, amyloid-related imaging abnormalities.

SELECT SAFETY INFORMATION **CONTRAINDICATION**

Contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis.

Please see additional Select Safety Information throughout. Please see full [Prescribing Information](#) for LEQEMBI, including Boxed WARNING.

 **LEQEMBI®**
(lecanemab-irmb)

Why identification and early intervention with LEQEMBI[®] matters


The underlying pathology of AD begins years before the symptoms appear¹

In the early stages of AD, mild cognitive symptoms are present. However, patients may not recognize them. Family or friends may be the first to notice these subtle changes and help their loved ones seek medical care.¹

Mild cognitive impairment (MCI) due to AD presents as subtle problems with memory, language, and thinking that can be confused with normal signs of aging.¹

When you recognize the warning signs of MCI due to AD, you have a better chance of early intervention and implementing appropriate treatment options.¹

MCI due to AD and mild AD dementia are different stages of disease and critical points for intervention¹



The stages of AD depicted above in equal size are not necessarily equal in duration.



The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit.^{2,3}

AD, Alzheimer's disease; MCI, mild cognitive impairment.

Please see additional Select Safety Information throughout. Please see full [Prescribing Information](#) for LEQEMBI, including Boxed WARNING.

 **LEQEMBI[®]**
(lecanemab-irmb)

Step 1

Assess patient eligibility and readiness for LEQEMBI®

Proactive steps to diagnose AD at the earliest symptomatic stages

✓ CHECK FOR COGNITIVE IMPAIRMENT⁴⁻⁷



- Patient history/informant observations
- Physical/neurological exams
- Assess the patient's function
 - A functional assessment may be required to start an eligible patient on therapy
 - Consider using a functional assessment used to identify daily activity such as: FAQs, FAST, CDR-SB
- Many neurocognitive tests are available to aid in the diagnosis of dementia or dementia due to AD, but not every test has the sensitivity to assess a patient with MCI

Consider using MCI due to AD–sensitive and/or mild AD dementia–sensitive cognitive assessments to identify early stages of AD

- Cognitive assessments available such as: **MoCA, SLUMS, AD8, and Mini-Cog®**

✓ RULE OUT NON-AD CAUSES^{4,8,9}



- Lab tests can rule out other causes such as vitamin B₁₂ deficiency and thyroid diseases
- Medications/comorbidities could be underlying causes
- **CT scans or MRI can rule out other causes** such as tumors, evidence of strokes, damage from severe head trauma, or a build-up of fluid in the brain

✓ CONFIRM AD DIAGNOSIS¹⁰⁻¹²



- A biomarker-confirmed AD diagnosis allows for the identification of patients appropriate for amyloid beta (Aβ)-targeting therapy, like LEQEMBI
- **Options for performing Aβ confirmation include amyloid PET scans, CSF, and FDA-cleared and other commercially available blood-based biomarkers (BBMs)**

AD, Alzheimer's disease; AD8, Eight-item Informant Interview to Differentiate Aging and Dementia; BBM, blood-based biomarkers; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CSF, cerebrospinal fluid; CT, computed tomography; FAQ, Functional Activities Questionnaire; FAST, Functional Assessment Staging Tool; FDA, US Food and Drug Administration; MoCA, Montreal Cognitive Assessment; MRI, magnetic resonance imaging; PET, positron emission tomography; SLUMS, Saint Louis University Mental Status Examination.

SELECT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

AMYLOID-RELATED IMAGING ABNORMALITIES

Medications in this class, including LEQEMBI, can cause ARIA-E, which can be observed on MRI as brain edema or sulcal effusions, and ARIA-H, which includes microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with AD, particularly in patients with MRI findings suggestive of cerebral amyloid angiopathy (CAA), such as pretreatment microhemorrhage or superficial siderosis. ARIA-H generally occurs with ARIA-E. Reported ARIA symptoms may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms usually resolve over time.


Please see additional Select Safety Information throughout.
Please see full [Prescribing Information](#) for LEQEMBI,
including Boxed WARNING.



Assess patient eligibility and readiness for LEQEMBI®

When making critical treatment decisions, talk with your patients about their readiness for starting LEQEMBI

- Individual **patient factors and circumstances** must be taken into account, including treatment goals and availability for repeated infusions and MRI scans
- Assess **nonclinical considerations** that may contribute to treatment success, including:
 - Patients motivated to seek treatment
 - Presence of care partner that can help navigate treatment
 - Patients who are willing to commit to MRI and infusion schedules



As you talk with patients about starting LEQEMBI, discuss the additional maintenance dosing options they'll have after completing 18 months of treatment²

Initiation period (first 18 months): Patients will receive twice-monthly infusions (once every 2 weeks).²

Maintenance period (after 18 months): Patients may transition to once-monthly infusions (once every 4 weeks) or once-weekly at-home subcutaneous injections with **LEQEMBI IQLIK**. At the discretion of the physician, patients may also continue receiving twice-monthly infusions.²

Things to consider when deciding on a maintenance option for your patient:

Clinical considerations before transitioning to maintenance dosing²:

- Patient has completed 18 months of **LEQEMBI** infusion initiation therapy and is clinically stable based on clinician assessment (or judgment)

Transition to **LEQEMBI IQLIK** if patient:

- Feels comfortable self-injecting or has a designated care partner who can support at-home injections
- Travels while still staying on schedule*

Stay on infusion if patient:

- Benefits from the community aspect of infusion site

*Once the autoinjector has come to room temperature (77° F/25° C) it should be maintained at that temperature in the original carton for up to 14 days. It cannot go back into the refrigerator.

Step 2a

Evaluate ARIA risk and prepare to start treatment

What is ARIA?

ARIA is a potential side effect of monoclonal antibodies, like LEQEMBI®, and can occur spontaneously in patients with AD.²

LEQEMBI can cause ARIA, which can present in 2 ways:

ARIA-E²

Presents as temporary swelling in areas of the brain and usually resolves over time

ARIA-H²

Presents as small spots of bleeding in or on the surface of the brain; infrequently, larger areas of bleeding in the brain can occur

ARIA usually occurs early in treatment and is mostly asymptomatic²

- Symptomatic ARIA occurred in 3% (29/898) and serious symptoms associated with ARIA occurred in 0.7% (6/898) of patients treated with LEQEMBI. ARIA can be fatal²
- Clinical symptoms associated with ARIA resolved in 79% (23/29) of patients during the period of observation²
- ARIA-H that occurred with ARIA-E tended to occur early (within 6 months)¹³
- Serious events of ARIA occurred in 3% of ApoE ε4 homozygotes and in ~1% of the heterozygotes and noncarriers²

Incidence of ARIA ^{2,3}		LEQEMBI	Placebo
ARIA incidence		(n=898) % (n)	(n=897) % (n)
ARIA-E or ARIA-H*		21 (191)	9 (84)
ARIA-E		13 (113)	2 (15)
ARIA-H		17 (152)	9 (80)
Isolated ARIA-H		8.9 (80)	7.8 (70)

*Including asymptomatic radiographic events.²

ARIA-E: ARIA with edema can be observed on MRI as brain edema or sulcal effusions.²

ARIA-H: ARIA with hemosiderin deposition includes microhemorrhage and superficial siderosis.²


AD, Alzheimer's disease; ApoE ε4, apolipoprotein E ε4; ARIA, amyloid-related imaging abnormalities; ARIA-E, amyloid-related imaging abnormalities-edema; ARIA-H, amyloid-related imaging abnormalities-hemosiderin deposition.

Please see additional Select Safety Information throughout.
Please see full [Prescribing Information](#) for LEQEMBI,
including Boxed WARNING.



The incidence of ARIA decreased after 12 months as patients continued therapy with LEQEMBI®¹⁴

Clarity AD Core period and LTE: Rates of ARIA-E and ARIA-H by years*¹⁴



*Infusion only data.¹⁴
Cutoff: March 31, 2025.¹⁴
The LTE study is ongoing.¹⁵

Imaging requirements and genetic testing recommendations are in place to help you assess and manage ARIA risk

- A baseline MRI is required to initiate LEQEMBI therapy as well as 4 MRIs, each prior to the 3rd, 5th, 7th, and 14th infusions to monitor for ARIA²
- ApoE ε4 testing is recommended to establish ARIA risk but is not required^{2,16}
- Throughout treatment, if a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including an MRI if indicated²



LTE, long-term extension.

SELECT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

AMYLOID-RELATED IMAGING ABNORMALITIES (cont'd)

Incidence of ARIA

Neuroimaging findings that may indicate CAA include evidence of prior ICH, cerebral microhemorrhage, and cortical superficial siderosis. CAA has an increased risk for ICH. The presence of an ApoE ε4 allele is also associated with CAA. Symptomatic ARIA occurred in 3% and serious ARIA symptoms in 0.7% with LEQEMBI. Clinical ARIA symptoms resolved in 79% of patients during the period of observation. ARIA, including asymptomatic radiographic events, was observed: LEQEMBI, 21%; placebo, 9%. ARIA-E was observed: LEQEMBI, 13%; placebo, 2%. ARIA-H was observed: LEQEMBI, 17%; placebo, 9%. No increase in isolated ARIA-H was observed for LEQEMBI vs placebo.

Please see additional Select Safety Information throughout.
Please see full [Prescribing Information](#) for LEQEMBI,
including Boxed WARNING.



Step 2b

Confirm eligibility and enrollment in an AD registry if required for LEQEMBI® coverage

Assess patient's insurance coverage. Confirm eligibility and enrollment in an AD registry if required for LEQEMBI coverage.

AD registries collect basic information, which may include:



Site of care



Treatment eligibility assessment



Medical history and/or imaging

Scan below to explore AD registry resources and enroll patients



ALZ-NET



CMS Registry



LEQEMBI Companion is by their side

No matter where patients are in treatment, the LEQEMBI Companion™ program is by their side.

As a part of the LEQEMBI Companion program, Eisai Patient Support (EPS) offers information and resources for accessing LEQEMBI for eligible patients. Once enrolled in the LEQEMBI Companion Program, patients will be connected with a dedicated Patient Navigator, who can help them understand insurance coverage, identify financial support, find infusion centers, and know what to expect at each step.

Call 1-833-453-7362 (1-833-4-LEQEMBI). For more information about the LEQEMBI Companion program, visit LEQEMBI.com/PatientSupport

Visit LEQEMBIEnrollment.com to learn how to get patients started

AD, Alzheimer's disease; ALZ-NET, Alzheimer's Network for Treatment and Diagnostics; CMS, Centers for Medicare & Medicaid Services.

SELECT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)


AMYLOID-RELATED IMAGING ABNORMALITIES (cont'd)

Incidence of ICH

ICH >1 cm in diameter was reported in 0.7% with LEQEMBI vs 0.1% with placebo. Fatal events of ICH in patients taking LEQEMBI have been observed.

Please see additional Select Safety Information throughout.
Please see full [Prescribing Information](#) for LEQEMBI,
including Boxed WARNING.





Other resources include:

The LEQEMBI® Companion™ app

➤ **A digital partner for your patients, featuring:**

- Educational resources to help set expectations and prepare for infusions
- A place to store contact information for their care team
- Customizable reminders for infusion appointments and related visits
- Personalized tips and real-patient stories to encourage ongoing engagement

➤ **LEQEMBI® IQLIK™ Injection support:**

- If a patient has been prescribed LEQEMBI IQLIK (subcutaneous injection), they can access resources focused on getting started and staying on track with their treatment schedule

Lance is an actual LEQEMBI patient and Liz is his care partner. People shown were compensated for their time, and information is accurate as of April 2025.

SELECT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

AMYLOID-RELATED IMAGING ABNORMALITIES (cont'd)

Risk Factors of ARIA and ICH

ApoE ε4 Carrier Status

Of the patients taking LEQEMBI, 16% were ApoE ε4 homozygotes, 53% were heterozygotes, and 31% were noncarriers. With LEQEMBI, ARIA was higher in ApoE ε4 homozygotes (LEQEMBI: 45%; placebo: 22%) than in heterozygotes (LEQEMBI: 19%; placebo: 9%) and noncarriers (LEQEMBI: 13%; placebo: 4%). Symptomatic ARIA-E occurred in 9% of ApoE ε4 homozygotes vs 2% of heterozygotes and 1% of noncarriers. Serious ARIA events occurred in 3% of ApoE ε4 homozygotes and in ~1% of heterozygotes and noncarriers. The recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers.

Please see additional Select Safety Information throughout.
Please see full [Prescribing Information](#) for LEQEMBI,
including Boxed WARNING.




Step 3a

Initiate treatment and monitor

Only LEQEMBI® empowers patients with maintenance dosing options to help them continue their treatment journey^{2,17}

A baseline MRI is required to initiate treatment.²



At 12-month appointment



Discuss the maintenance treatment options with your patients and assess their level of interest in either **continuing with infusion treatment (twice-monthly [once every 2 weeks] or once-monthly maintenance)** or **switching to the subcutaneous injection at 18 months.**²

Take the opportunity to:

- Identify whether the patient is appropriate for and motivated to continue therapy
- Assess which long-term maintenance dose formulation is appropriate to use
- Schedule their next follow-up appointment

AD, Alzheimer's disease; ARIA, amyloid-related imaging abnormalities; HCP, health care professional; IV, intravenous; MRI, magnetic resonance imaging; SC, subcutaneous.

SELECT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

AMYLOID-RELATED IMAGING ABNORMALITIES (cont'd)

Risk Factors of ARIA and ICH (cont'd)

Radiographic Findings of CAA

Neuroimaging findings that may indicate CAA include evidence of prior ICH, cerebral microhemorrhage, and cortical superficial siderosis. CAA has an increased risk for ICH. The presence of an ApoE ε4 allele is also associated with CAA.

Please see additional Select Safety Information throughout.

Please see full [Prescribing Information](#) for LEQEMBI, including Boxed WARNING.



Initiate treatment and monitor

The first and only anti-amyloid therapy to offer at-home injection to help patients continue their treatment journey after 18 months^{2,16}



- › **Once-weekly** at-home subcutaneous administration²
- › **Prepare, inject in 15 seconds, and dispose²**
- › **Single-dose prefilled autoinjector:** 360 mg/1.8 mL (200 mg/mL)²
- › For detailed information on how to prepare, administer, and safely dispose of LEQEMBI IQLIK, review and advise the patient and/or care partner to read the FDA-approved patient labeling (Medication Guide and Instructions for Use)
- › During maintenance dosing, patients may switch from infusion (once every 4 weeks) to subcutaneous LEQEMBI IQLIK (once weekly), or vice versa. Initiate this transition at 1 week after the last maintenance dose²
- › Monitor for signs and symptoms of an injection reaction²

Consider which patients are appropriate candidates for LEQEMBI® IQLIK™:

- › Feel comfortable using an autoinjector, or have a designated care partner who can support once-weekly at-home injections
- › Travel while still staying on schedule*

*Once the autoinjector has come to room temperature (77 °F/25 °C), it should be maintained at that temperature. It cannot go back into the refrigerator.²

When to start transition based on change of dosing option²

Current route of administration/dosing	Updated route of administration/dosing	Transition timing
IV initiation (every 2 weeks)	IV maintenance (every 4 weeks)	Start 2 weeks after last infusion
	SC maintenance (every week)	
IV maintenance (every 4 weeks)	SC maintenance (every week)	Start 1 week after last infusion
SC maintenance (every week)	IV maintenance (every 4 weeks)	Start 1 week after last injection

Please see additional Select Safety Information throughout.
Please see full [Prescribing Information](#) for LEQEMBI,
including Boxed WARNING.



Step 3b

Coordinate with infusion site staff to ensure starting IV treatment is smooth

Preparing patients for infusion²

- 1 Calculate the dose (mg), the total volume (mL) of LEQEMBI[®] solution required, and the number of vials needed based on the patient's actual body weight and recommended dose of 10 mg/kg. Each vial contains a LEQEMBI concentration of 100 mg/mL²



Determine patient's dose with the LEQEMBI Dosing Calculator

- 2 Prior to administration, LEQEMBI must be diluted in 250 mL of 0.9% Sodium Chloride Injection, USP²

- Consider checking the medical record for any weight changes prior to each infusion

Initiate and maintain treatment with LEQEMBI and monitor for safety

Dilution²

- Each mL of solution contains 100 mg of lecanemab-irmb and arginine hydrochloride (42.13 mg), histidine (0.18 mg), histidine hydrochloride monohydrate (4.99 mg), polysorbate 80 (0.50 mg), and water for injection at an approximate pH of 5.0
- Before every infusion, calculate the dose (mg), the total volume (mL) of LEQEMBI solution required, and the number of vials needed based on the patient's actual body weight and the recommended dose of 10 mg/kg
- Use aseptic technique when preparing the LEQEMBI diluted solution for infusion
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Check that the LEQEMBI solution is clear to opalescent and colorless to pale yellow. Do not use if opaque particles, discoloration, or other foreign particles are present
- Remove the flip-off cap from the vial. Insert the sterile syringe needle into the vial through the center of the rubber stopper
- Withdraw the required volume of LEQEMBI from the vial(s) and add to an infusion bag containing 250 mL of 0.9% Sodium Chloride Injection, USP
- Each vial is for one-time use only. Discard any unused portion
- Gently invert the infusion bag containing the LEQEMBI diluted solution to mix completely. Do not shake
- After dilution, immediate use is recommended. If not administered immediately, store LEQEMBI refrigerated at 2°C to 8°C (36°F to 46°F) for up to 4 hours, or at room temperature up to 30°C (86°F) for up to 4 hours. Do not freeze

IV, intravenous.

Please see additional Select Safety Information throughout. Please see full [Prescribing Information](#) for LEQEMBI, including Boxed WARNING.



Coordinate with infusion site staff to ensure starting IV treatment is smooth

Administration²

- Visually inspect the diluted LEQEMBI® solution for particles or discoloration prior to administration. Do not use if it is discolored, or opaque, or foreign particles are seen
- Prior to infusion, allow the diluted LEQEMBI solution to warm to room temperature
- Infuse the entire volume of the diluted LEQEMBI solution intravenously for approximately 1 hour through an IV line containing a terminal low-protein binding 0.2 micron in-line filter. Flush infusion to ensure all LEQEMBI is administered
- Monitor for any signs or symptoms of an infusion-related reaction. The infusion rate may be reduced, or the infusion may be discontinued, and appropriate therapy administered as clinically indicated. Consider pre-medication at subsequent dosing with antihistamines, nonsteroidal anti-inflammatory drugs, or corticosteroids

Follow-up infusions²

- After each infusion, ensure the patient/care partner has confirmed an appointment for their next infusion in 2 to 4 weeks, depending if they are in initiation or maintenance phase
- **Respond promptly to any inbound requests from infusion sites; they may need specific paperwork to confirm patient eligibility and ensure reimbursement**
- Ensure regular follow-up with patients to ensure compliance and address any questions



To identify an infusion site near your practice, visit [LeqembiLocator.com](https://www.leqembi.com/locator)

SELECT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

AMYLOID-RELATED IMAGING ABNORMALITIES (cont'd)

Risk Factors of ARIA and ICH (cont'd)

Radiographic Findings of CAA (cont'd)

The baseline presence of at least 2 microhemorrhages or the presence of at least 1 area of superficial siderosis on MRI, which may be suggestive of CAA, have been identified as risk factors for ARIA. Patients were excluded from Clarity AD for the presence of >4 microhemorrhages and additional findings suggestive of CAA (prior cerebral hemorrhage >1 cm in greatest diameter, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of ICH.

Please see additional Select Safety Information throughout.
Please see full [Prescribing Information](#) for LEQEMBI,
including Boxed WARNING.



Step 3c

Perform follow-up MRIs to monitor for ARIA^{2,18}

Proactively coordinate infusion and MRI schedules with infusion sites and neuroradiologists to ensure all scans are completed prior to the associated infusions²

➤ Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI^{®2}

Monitoring and scheduling infusions²

Obtain a recent brain MRI prior to initiating therapy with LEQEMBI¹

In general, the MRI should be performed within approximately 1 week before the scheduled infusion of LEQEMBI and reviewed prior to proceeding with the infusion

Infusion #

1 2 3 4 5 6 7 8 9 10 11 12 13 14



MRI



MRI



MRI



MRI

- If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including MRI if indicated²
- In clinical trials, monitoring MRIs were scheduled after patients tolerated the first dose well²
- Give neuroradiology adequate read and evaluation time when scheduling MRIs, and yourself enough time to interpret the results
- Communicate openly with key stakeholders about infusion and MRI scheduling and any safety concerns

If ARIA is observed on MRI^{2,18}

- Careful clinical evaluation should be performed prior to continuing treatment
- Confirm the next appointment and discuss any possible obstacles or barriers to care

SELECT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

AMYLOID-RELATED IMAGING ABNORMALITIES (cont'd)

Risk Factors of ARIA and ICH (cont'd)

Concomitant Antithrombotic or Thrombolytic Medication

In Clarity AD, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. Most exposures were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of ICH: 0.9% in patients taking LEQEMBI with a concomitant antithrombotic medication vs 0.6% with no antithrombotic and 2.5% in patients taking LEQEMBI with an anticoagulant alone or with antiplatelet medication such as aspirin vs none in patients receiving placebo.

Fatal cerebral hemorrhage has occurred in 1 patient taking an anti-amyloid monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of a thrombolytic agent.

Please see additional Select Safety Information throughout.
Please see full [Prescribing Information](#) for LEQEMBI,
including Boxed WARNING.



If ARIA is present, know the recommendations and be prepared to adjust the patient's infusion schedule^{2,18}

ARIA-E severity on MRI ²			
Clinical symptom severity*	Mild	Moderate	Severe
Asymptomatic	May continue dosing	Suspend dosing [†]	Suspend dosing [†]
Mild	May continue dosing based on clinical judgment		
Moderate or severe	Suspend dosing [†]		

ARIA-H severity on MRI ²			
Clinical symptom severity	Mild	Moderate	Severe
Asymptomatic	May continue dosing	Suspend dosing [†]	Suspend dosing [§]
Symptomatic	Suspend dosing [†]		

*Mild: Discomfort noticed, but no disruption of normal daily activity. Moderate: Discomfort sufficient to reduce or affect normal daily activity. Severe: Incapacitating, with inability to work or to perform normal daily activity.

[†] Suspend until MRI demonstrates radiographic resolution and symptoms, if present, resolve; consider a follow-up MRI to assess resolution 2 to 4 months after initial identification. Resumption of dosing should be guided by clinical judgment.

[‡] Mild/moderate: Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; resumption of dosing should be guided by clinical judgment; consider a follow-up MRI to assess for stabilization 2 to 4 months after initial identification.

[§] Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; use clinical judgment in considering whether to continue treatment or permanently discontinue LEQEMBI.

- In patients who suspend dosing due to ARIA, consider a follow-up MRI to assess for resolution 2 to 4 months after initial identification²
- Recommendations for dosing in patients with ARIA-E and ARIA-H depend on clinical symptoms and radiographic severity²

Throughout treatment, if a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including an MRI if indicated²

ARIA, amyloid-related imaging abnormalities; ARIA-E, amyloid-related imaging abnormalities-edema; ARIA-H, amyloid-related imaging abnormalities-hemosiderin deposition; MRI, magnetic resonance imaging.

Please see additional Select Safety Information throughout. Please see full [Prescribing Information](#) for LEQEMBI, including Boxed WARNING.



Step 3d

Connect with key stakeholders to help patients start and stay on treatment

As you navigate LEQEMBI® treatment, consider implementing these steps in your practice:



Perform baseline MRI and consider conducting subsequent MRIs with the same imaging center²



Communicate clearly with patient and/or care partners to help them feel invested in their care



Perform functional and cognitive assessments to confirm current disease stage¹



Give neuroradiology adequate evaluation time when scheduling each MRI



Confirm A β pathology with PET, CSF, or blood-based biomarkers (BBMs)



Coordinate with infusion sites about any safety concerns



Recommend testing for ApoE ϵ 4 to identify patients at elevated risk of ARIA²



Communicate with infusion sites on potential changes to dosing after 18 months on therapy²



Request that neuroradiologist documents the presence or absence of ARIA in the EMR

ApoE ϵ 4, apolipoprotein E ϵ 4; ARIA, amyloid-related imaging abnormalities; CSF, cerebrospinal fluid; EMR, electronic medical record; MRI, magnetic resonance imaging; PET, positron emission tomography.

SELECT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

AMYLOID-RELATED IMAGING ABNORMALITIES (cont'd)

Risk Factors of ARIA and ICH (cont'd)

Concomitant Antithrombotic or Thrombolytic Medication (cont'd)

Additional caution should be exercised when considering the administration of antithrombotics or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI®. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with LEQEMBI.

Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for ICH and, in particular, patients who need to be on anticoagulant therapy or patients with findings on MRI that are suggestive of CAA.

**Please see additional Select Safety Information throughout.
Please see full [Prescribing Information](#) for LEQEMBI,
including Boxed WARNING.**



SELECT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

AMYLOID-RELATED IMAGING ABNORMALITIES (cont'd)

Radiographic Severity With LEQEMBI

Most ARIA-E radiographic events occurred within the first 7 doses, although ARIA can occur at any time, and patients can have >1 episode. Maximum radiographic severity of ARIA-E with LEQEMBI was mild in 4%, moderate in 7%, and severe in 1% of patients. Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. Maximum radiographic severity of ARIA-H microhemorrhage with LEQEMBI was mild in 9%, moderate in 2%, and severe in 3% of patients; superficial siderosis was mild in 4%, moderate in 1%, and severe in 0.4% of patients. With LEQEMBI, the rate of severe radiographic ARIA-E was highest in ApoE ε4 homozygotes (5%) vs heterozygotes (0.4%) or noncarriers (0%). With LEQEMBI, the rate of severe radiographic ARIA-H was highest in ApoE ε4 homozygotes (13.5%) vs heterozygotes (2.1%) or noncarriers (1.1%).

Monitoring and Dose Management Guidelines

Baseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment. Depending on ARIA-E and ARIA-H clinical symptoms and radiographic severity, use clinical judgment when considering whether to continue dosing or to temporarily or permanently discontinue LEQEMBI. If a patient experiences ARIA symptoms, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.

HYPERSENSITIVITY REACTIONS

Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction and initiate appropriate therapy.

INFUSION-RELATED REACTIONS (IRRs)

IRRs were observed—LEQEMBI: 26%; placebo: 7%—and most cases with LEQEMBI (75%) occurred with the first infusion. IRRs were mostly mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.

IRRs can occur during or after the completion of infusion. In the event of an IRR during the infusion, the infusion rate may be reduced or discontinued, and appropriate therapy initiated as clinically indicated. Consider prophylactic treatment prior to future infusions with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids.

ADVERSE REACTIONS

- The most common adverse reactions reported in ≥5% with LEQEMBI infusion every 2 weeks and ≥2% higher than placebo were IRRs (LEQEMBI: 26%; placebo: 7%), ARIA-H (LEQEMBI: 14%; placebo: 8%), ARIA-E (LEQEMBI: 13%; placebo: 2%), headache (LEQEMBI: 11%; placebo: 8%), superficial siderosis of central nervous system (LEQEMBI: 6%; placebo: 3%), rash (LEQEMBI: 6%; placebo: 4%), and nausea/vomiting (LEQEMBI: 6%; placebo: 4%)
- Safety profile of LEQEMBI IQLIK for maintenance treatment was similar to LEQEMBI infusion. Patients who received LEQEMBI IQLIK experienced localized and systemic (less frequent) injection-related reactions (mild to moderate in severity)

LEQEMBI (lecanemab-irmb) is available:

- Intravenous infusion: 100 mg/mL
- Subcutaneous injection: 200 mg/mL

Discover how to intervene early for patients with MCI due to AD or mild AD dementia^{2,3}



Visit
Leqembihcp.com
to learn more

Lance is an actual LEQEMBI patient. People shown were compensated for their time, and information is accurate as of April 2025.

SUMMARY OF WARNINGS & PRECAUTIONS:

- Amyloid-Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI. Risk of ARIA, including symptomatic ARIA, was increased in apolipoprotein E ϵ 4 homozygotes compared to heterozygotes and noncarriers. The risk of ARIA-E and ARIA-H is increased in patients with pretreatment microhemorrhages and/or superficial siderosis. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including MRI scanning if indicated.
- Infusion-Related Reactions: The infusion rate may be reduced, or the infusion may be discontinued, and appropriate therapy administered as clinically indicated. Consider pre-medication at subsequent dosing with antihistamines, non-steroidal anti-inflammatory drugs, or corticosteroids

AD, Alzheimer's disease; ARIA-E, amyloid-related imaging abnormalities-edema; ARIA-H, amyloid-related imaging abnormalities-hemosiderin deposition; MRI, magnetic resonance imaging.

Please see additional Select Safety Information throughout.

Please see full [Prescribing Information](#) for LEQEMBI, including Boxed WARNING.

References: **1.** Alzheimer's Association. 2025 Alzheimer's disease facts and figures. *Alzheimers Dement.* 2025;21:e70235. doi:10.1002/alz.70235 **2.** LEQEMBI (lecanemab-irmb) [package insert]. Nutley, NJ: Eisai Inc. **3.** van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med.* 2023;388(1):9-21. **4.** Alzheimer's Association. Medical tests for diagnosing Alzheimer's. Accessed July 7, 2025. https://www.alz.org/alzheimers-dementia/diagnosis/medical_tests **5.** O'Caomh R, Timmons S, Molloy DW. Screening for mild cognitive impairment: comparison of "MCI specific" screening instruments. *J Alzheimers Dis.* 2016;51(2):619-629. **6.** Tariq SH, Tumosa N, Chibnall JT, Perry MH 3rd, Morley JE. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder—a pilot study. *Am J Geriatr Psychiatry.* 2006;14(11):900-910. **7.** Usarel C, Dokuzlar O, Aydin AE, Soysal P, Isik AT. The AD8 (Dementia Screening Interview) is a valid and reliable screening scale not only for dementia but also for mild cognitive impairment in the Turkish geriatric outpatients. *Int Psychogeriatr.* 2019;31(2):223-229. **8.** Budson AE, Solomon PR. Evaluating the patient with memory loss or dementia. In: Budson AE, Solomon PR, eds. *Memory Loss, Alzheimer's Disease, and Dementia: A Practical Guide for Clinicians.* 3rd ed. Elsevier; 2022:4-37. **9.** National Institute on Aging. How biomarkers help diagnose dementia. Accessed July 7, 2025. <https://www.nia.nih.gov/health/how-biomarkers-help-diagnose-dementia> **10.** Schindler SE, Bollinger JG, Ovoid V, et al. High-precision plasma β -amyloid 42/40 predicts current and future brain amyloidosis. *Neurology.* 2019;93(17):e1647-e1659. **11.** Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid- β biomarkers for Alzheimer's disease. *Nature.* 2018;554(7691):249-254. **12.** Angioni D, Delrieu J, Hansson O, et al. Blood biomarkers from research use to clinical practice: what must be done? A report from the EU/US CTAD task force. *J Prev Alzheimers Dis.* 2022;9(4):569-579. **13.** Iwatsubo T, Irizarry M, van Dyck C, Sabbagh M, Bateman R, Cohen S. 2022 Clarity AD CTAD Presentations. Clarity AD: a Phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer's disease. Paper presented at: Clinical Trials on Alzheimer's Disease; November 29-December 2, 2022; San Francisco, CA. **14.** Data on file. 48-month safety summary. Eisai Inc., Nutley, NJ. **15.** Data on file. Clarity AD OLE extension. Eisai Inc., Nutley, NJ. **16.** Konijnenberg J, Tijms BM, Gobom J, et al. APOE 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. *Alzheimers Res Ther.* 2020;12(1):65. doi:10.1186/s13195-020-00628-z **17.** Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA.* 2023;330(6):512-527. **18.** Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. *Brain.* 2023;146(11):4414-4424.



LEQEMBI® IQLIK™ and LEQEMBI® Companion™ are trademarks of Eisai R&D Management Co., Ltd. LEQEMBI® is a registered trademark of Eisai R&D Management Co., Ltd. © 2025 Eisai Inc. and Biogen. All trademarks and company names are the property of their respective owners. LEQE-US4961 09/2025

